Rhumbline Advisers Acquires 6,070 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Rhumbline Advisers raised its holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 13.9% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 49,660 shares of the company’s stock after acquiring an additional 6,070 shares during the quarter. Rhumbline Advisers owned approximately 0.13% of Tarsus Pharmaceuticals worth $1,350,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Tarsus Pharmaceuticals by 33.4% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,109 shares of the company’s stock valued at $166,000 after acquiring an additional 1,530 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Tarsus Pharmaceuticals by 27.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 122,634 shares of the company’s stock worth $3,333,000 after buying an additional 26,225 shares during the period. Assenagon Asset Management S.A. purchased a new stake in shares of Tarsus Pharmaceuticals in the 2nd quarter worth $28,904,000. Janus Henderson Group PLC purchased a new stake in shares of Tarsus Pharmaceuticals in the 1st quarter worth $313,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Tarsus Pharmaceuticals in the 1st quarter worth $12,640,000. Institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Trading Down 0.3 %

Shares of NASDAQ TARS opened at $34.51 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.03 and a quick ratio of 6.99. The stock has a market capitalization of $1.30 billion, a P/E ratio of -7.23 and a beta of 1.06. Tarsus Pharmaceuticals, Inc. has a 1-year low of $12.57 and a 1-year high of $42.50. The business has a fifty day moving average price of $27.44 and a 200 day moving average price of $31.05.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.98) by $0.10. The firm had revenue of $40.81 million during the quarter, compared to analysts’ expectations of $31.30 million. Tarsus Pharmaceuticals had a negative return on equity of 63.99% and a negative net margin of 180.00%. During the same period in the prior year, the business posted ($1.17) EPS. Equities research analysts expect that Tarsus Pharmaceuticals, Inc. will post -3.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have weighed in on TARS. William Blair upgraded Tarsus Pharmaceuticals to a “strong-buy” rating in a report on Friday, August 30th. Oppenheimer reiterated an “outperform” rating and issued a $63.00 target price (up from $61.00) on shares of Tarsus Pharmaceuticals in a report on Friday, August 9th. One research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Tarsus Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $51.60.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.